How the EPO treats personalised healthcare patents

Personalised healthcare, or precision medicine, is an evolving field where a therapeutic treatment is tailored to an individual with a particular disease. The aim is to target the right treatment to the right patient, typically by using a diagnostic test (companion diagnostic test) for one or more biomarkers indicative of drug response.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

4 June 2026 The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.

Biotechnology

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

Biotechnology

Closing the women's health gap offers ‘benefits for all’

7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.

More features

‘When a UPC judge wears their robe, they have no gender’

Ex-Kirkland patent litigator jumps to rival firm

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Heated LNP litigation puts Moderna and Acuitas in the spotlight

UPC dispute resolution forum opens with ceremony in Slovenia

Kirkland & Ellis adds leading barrister in London

European court backs AstraZeneca unit in blood cancer combo dispute

Boehringer Ingelheim adds ex-Teva executive to patent team

How the EPO treats personalised healthcare patents

More on this story

Editor's picks

Editor's picks

More features